- Home
- EUDA vs LPTX Comparison
EUDA vs LPTX Comparison
Compare EUDA & LPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EUDA
- LPTX
- Stock Information
- Founded
- EUDA 2021
- LPTX 2011
- Country
- EUDA Singapore
- LPTX United States
- Employees
- EUDA N/A
- LPTX N/A
- Industry
- EUDA Blank Checks
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EUDA Finance
- LPTX Health Care
- Exchange
- EUDA Nasdaq
- LPTX Nasdaq
- Market Cap
- EUDA 146.0M
- LPTX 119.6M
- IPO Year
- EUDA N/A
- LPTX N/A
- Fundamental
- Price
- EUDA $3.69
- LPTX $0.30
- Analyst Decision
- EUDA
- LPTX Buy
- Analyst Count
- EUDA 0
- LPTX 2
- Target Price
- EUDA N/A
- LPTX $8.00
- AVG Volume (30 Days)
- EUDA 83.2K
- LPTX 3.3M
- Earning Date
- EUDA 01-01-0001
- LPTX 08-11-2025
- Dividend Yield
- EUDA N/A
- LPTX N/A
- EPS Growth
- EUDA N/A
- LPTX N/A
- EPS
- EUDA N/A
- LPTX N/A
- Revenue
- EUDA $4,011,005.00
- LPTX N/A
- Revenue This Year
- EUDA $212.19
- LPTX N/A
- Revenue Next Year
- EUDA $254.35
- LPTX N/A
- P/E Ratio
- EUDA N/A
- LPTX N/A
- Revenue Growth
- EUDA 8.22
- LPTX N/A
- 52 Week Low
- EUDA $2.92
- LPTX $0.22
- 52 Week High
- EUDA $6.30
- LPTX $4.79
- Technical
- Relative Strength Index (RSI)
- EUDA 49.31
- LPTX 30.76
- Support Level
- EUDA $3.52
- LPTX $0.27
- Resistance Level
- EUDA $3.75
- LPTX $0.30
- Average True Range (ATR)
- EUDA 0.20
- LPTX 0.04
- MACD
- EUDA 0.03
- LPTX -0.01
- Stochastic Oscillator
- EUDA 58.93
- LPTX 7.11
About EUDA EUDA Health Holdings Limited
EUDA Health Holdings Ltd is a non-invasive healthcare company across Southeast Asia and China. The Company has two reportable segments: property management services and holistic wellness consumer products and services. Key revenue is generated from property management services that include common area property management services that contain cleaning, landscaping, public facilities maintenance and other traditional services and also include security property management services provided to all tenants and property owners.
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .